Ministry selects cartilage-hair hypoplasia, Pearson syndrome, and other diseases
Comprehensively reviews age of onset, severity, and availability of treatment and management for genetic diseases

The Ministry of Health and Welfare said on October 15 that it had selected seven additional diseases for which genetic testing can be performed on embryos or fetuses.


Seven Diseases Added for Genetic Testing on Embryos and Fetuses, Bringing Total to 264 View original image

The newly added diseases are ▲homocystinuria-megaloblastic anemia, cblE type ▲cartilage-hair hypoplasia ▲TOR1A-related dystonia ▲SGCE-related dystonia ▲DPAGT1-related congenital myasthenic syndrome ▲Pearson syndrome and ▲epidermolytic palmoplantar keratoderma type 1. As a result, the total number of genetic diseases for which testing can be performed at the embryo or fetal stage has increased to 264.


The ministry currently manages the list of genetic diseases for which testing can be performed on embryos or fetuses, taking patients' requests into account. For diseases submitted for review, an expert committee comprehensively assesses factors including the age at symptom onset, fatality and severity, and the availability of treatment and management before selecting diseases eligible for testing.


Requests for disease reviews can be submitted through the e-People portal. Applicants must provide the disease name and the name of the causative gene, whether a genetic variant has been confirmed in the patient, the genetic test results, the relationship between the patient and the applicant, the patient's main symptoms, and the reason for the request.


This review covered diseases for which requests had been received by July 15. Four diseases related to hereditary tumor predisposition syndromes or cardiomyopathy are undergoing further review. The complete list of 264 diseases is available under “Notices” in the “Alerts” section of the ministry's website.



Kwak Sun-heon, the ministry's Director General for Health and Medical Policy, said, “We are providing support so that families with a history of genetic diseases can ease their anxiety about having a child with a fatal genetic disease and make plans for a safe delivery.” He added, “However, we are conducting careful reviews with medical and bioethics experts to protect the right to life of embryos or fetuses from undue concerns about genetic diseases, including cases where it is unclear whether the genetic variant listed in an application causes the disease.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing